In vitro synergistic activity of antibiotic combinations against Brucella melitensis using E-test methodology

Brazilian Journal of Microbiology

Volumn 39, Issue 2, 2008, Pages 233-237

  Kilic, Selcuk ^a,b,c  

^a Department of Communicable Diseases Research

^b GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^c Refik Saydam Hygiene Center   (Turkey)

Author keywords

Antibiotics; Brucella melitensis; Synergism

Indexed keywords

BRUCELLA MELITENSIS;

EID: 48849112203     PISSN: 15178382     EISSN: 16784405     Source Type: Journal    
DOI: 10.1590/S1517-83822008000200006     Document Type: Article

References (31)

1. Al Dahouk, S.; Hagen, R.M.; Nockler, K.; Tomaso, H.; Wittig, M.; Scholz, H.C.; Vergnaud, G.; Neubauer, H. (2005). Failure of a short-term antibiotic therapy for human brucellosis using ciprofloxacin. A study on in vitro susceptibility of Brucella strains. Chemotherapy, 6, 352-356.
2. Alton, G.G.; Jones, L.M.; Angus, R.D.; Verger, J.M. (1988). Techniques for the Brucellosis Laboratory. Paris: Institut National de la recherche Agronomique (INRA), p. 34-61.
3. Ariza, J.; Bocsh, J.; Gudiol, F.; Linares, J.; Fernandez, V.P.; Martin, R. (1986). Relevance of in vitro antimicrobial susceptibility of Brucella melitensis to relapse rate in human brucellosis. Antimicrob. Agents Chemoter., 30, 958-960.
4. Baykam, N.; Esener, H.; Ergonul, O.; Eren, S.; Celikbas, A.K., Dokuzoguz, B. (2004). In vitro antimicrobial susceptibility of Brucella species. Int. J. Antimicrob. Agents, 23, 405-407.
5. Bodur, H.; Balaban, N.; Aksaray, S.; Yetener, V.; Akinci, E.; Coplan, A.; Erbay, A. (2003). Biotypes and antimicrobial susceptibilities of Brucella isolates. Scand. J. Infect. Dis., 35, 337-338.
6. Bonapace, C.R.; White, R.L.; Friedrich, L.V.; Bosso, J.A. (2000). Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with Etest, time-kill, and checkerboard methods. Diagn. Microbiol. Infect. Dis., 1, 43-50.
7. Clinical and Laboratory Standards Institute (2006). Performance standards for antimicrobial susceptibility testing; Sixteenth informational supplement. CLSI document M 100-S16, Wayne, PA; USA.
8. Dizbay, M.; Kilic, S.; Hizel, K.; Arman, D. (2007). Tigecycline: its potential for treatment of brucellosis. Scand. J. Infect. Dis., 39 (5), 432-4.
9. Falagas, M.E.; Bliziotis, I.A. (2006). Quinolones for Treatment of Human Brucellosis: Critical Review of the Evidence from Microbiological and Clinical Studies. Antimicrob. Agents Chemother., 50, 22-33.
10. Food and Agriculture Organization-World Health Organization. Joint FAO/WHO Expert Committee on Brucellosis (sixth report) (1986) WHO Technical Report Series No. 740. Geneva, World Health Organisation, p. 56-57.
11. Garcia-Rodrigez, J.A.; Munoz Bellidio, J.L.; Fresnadillo, J.M.; Trujillano, I. (1993). In vitro activities of new Macrolides and Rifepentine against Brucella Spp. Antimicrob. Agents Chemother., 37, 911-913.
12. Gur, D.; Kocagoz, S.; Akova, M. (1999). Comparison of E-test to microdilution for determining in vitro activities of antibiotics against Brucella melitensis. Antimicrob. Agents Chemother., 43, 2337.
13. Hall, W.H. (1991). Modern chemotherapy for brucellosis in humans. Rev. Infect. Dis., 3, 1060-1099.
14. King, A. (2001). Recommendations for susceptibility tests on fastidious organisms and those requiring special handling. J. Antimicrob. Chemother., 48 (Suppl S1), 77-80.
15. Kinsara, A.; Al-Mowallad, A.; Osaba, A.O. (1999). Increasing resistance of Brucella to Co-Trimoxazole. Antimicrob. Agents Chemother., 6, 1531.
16. Kocagoz, S.; Akova, M.; Altun, B.; Gur, D.; Hascelik, G. (2002). In vitro activities of new quinolones against Brucella melitensis isolated in a tertiary-care hospital in Turkey. Clin. Microbiol. Infect., 8, 240-242.
17. Kose, S.; Kilic, S.; Ozbel, Y. (2005). Identification of Brucella species isolated from proven Brucellosis Patient in Izmir, Turkey. J. Basic Microbiol., 45, 323-327.
18. Lewis, R.E.; Diekema, D.J.; Messer, S.A.; Pfaller, M.A.; Klepser, M.E. (2002). Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. Antimicrob. Agents Chemother., 49, 345-351.
19. Lopez-Merino, A.; Contreras-Rodriguez, A.; Migranas-Ortiz, R.; Orrantia-Gradin, R.; Hernandez-Oliva, G.M.; Gutierrez-Rubio, A.T.; Cardenosa, O. (2004). Susceptibility of Mexican Brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis. Scand. J. Infect. Dis., 36, 636-638.
20. Madkour, M.M. (2001). Treatment. In: Madkour MM, (ed): Madkour's Brucellosis. Berlin Heidelberg New York: Springer-Verlag, p. 241-261.
21. Memish, Z.; Mah, M.W.; Al Mahmoud, S.; Al Shaalan, M.; Khan, M.Y. (2000). Brucella bacteraemia: Clinical and laboratory observations in 160 Patients. J. Infect., 1, 59-63.
22. Orhan, G.; Bayram, A.; Zer, Y.; Balci, I. (2005). Synergy tests by E-test and checkerboard methods of antimicrobial combinations against Brucella melitensis J. Clin. Microbiol., 43, 140-143.
23. Pankey, G.A.; Ashcraft, D. (2005). In Vitro Synergy of Ciprofloxacin and Gatifloxacin against Ciprofloxacin-Resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother., 7, 2959-2964.
24. Pappas, G.; Christou, L.; Akritidis, N.; Bosilkovski, M.; Tsianos, E. (2005). Brucellosis. N. Engl. J. Med., 352, 2325-2336.
25. Pappas, G.; Solera, J.; Akritidis, N.; Tsianos, E. (2005). New approaches to the antibiotic treatment of brucellosis. Int. J. Antimicrob. Agents, 26, 101-105.
26. Rubinstein, E.R.; Lang, R.; Shasha, B.; Hagar, B.; Diamanstein, L.; Joseph, G.; Anderson, M.; Harrison, K. (1991). In vitro susceptibility of Brucella melitensis to antibiotics. Antimicrob. Agents Chemother., 35, 1925-1927.
27. Solera, J.; Martinez-Alfaro, E.; Espinosa, A. (1997). Recognition and optimum treatment of brucellosis. Drugs, 53: 245-256.
28. Trujillano-Martin, I.; Garcia Sanchez, E.; Martinez, I.M.; Fresnadillo, M.J.; Garcia Sanchez, J.E.; Garcia-Rodrigez, J.A. (1999). In vitro activities of six new Fluoroquinoles against Brucella melitensis. Antimicrob. Agents Chemoter., 1, 194-195.
29. Turkmani, A.; Ioannidis, A.; Christidou, A.; Psaroulaki, A.; Loukaides, F.; Tselentis, Y. (2006). In vitro susceptibilities of Brucella melitensis isolates to eleven antibiotics. Annals Clin. Microbiol. Antimicrob., 5, 24-29.
30. White, R.L.; Burgess , D.S.; Manduru, M.; Bosso, J.A. (1996). Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E-Test. Antimicrob. Agents Chemother., 8, 1914-1918.
31. Yamazhan, T.; Aydemir, S.; Tunger, A.; Serter, D.; Gokengin, D. (2005). In vitro activities of various antimicrobials against Brucella melitensis strains in the Aegean Region in Turkey. Med. Princ. Pract., 14, 413-416.